STOFD: Solution Temperature and Fluid Deficit During Hysteroscopy

Sponsor
The University of Texas Health Science Center, Houston (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05622097
Collaborator
(none)
75
3
12

Study Details

Study Description

Brief Summary

Hysteroscopic surgery is widely used for the treatment of gynecological diseases, such as septum, synechiae, polyp and intrauterine fibroids. The complication rate is estimated as 0.22% and includes uterine perforation, massive bleeding, and fluid overload. Operative hysteroscopy intravascular absorption (OHIA) syndrome refers to fluid overload complications from operative hysteroscopies and is considered a major complication. Report describing the clinical association between irrigation fluid temperature to intravasation rate itself or the risk of fluid overload are limited mainly to theoretical models. Due to the aforementioned, we aim to evaluated the role of temperature on absorption of the irrigation solution in hysteroscopic surgery.

Condition or Disease Intervention/Treatment Phase
  • Other: 0.9% Saline warmed to 37 degrees Celsius
  • Other: 0.9% Saline warmed to 24 degrees Celsius
  • Other: 0.9% Saline cooled to 17 degrees Celsius
N/A

Detailed Description

Hysteroscopic surgery is widely used for the treatment of gynecological diseases, such as septum, synechiae, polyp and intrauterine fibroids. Advantages include less invasiveness and faster recovery compared to traditional laparotomy. The complication rate is estimated as 0.22% and includes uterine perforation, massive bleeding, and fluid overload.

Operative hysteroscopy intravascular absorption (OHIA) syndrome refers to fluid overload complications from operative hysteroscopies and is considered a major complication. Although rare, large-scale fluid absorption might lead to symptoms severe enough to require intensive care including dilutional hyponatremia, hypoosmolality, brain oedema, hypokinetic circulation and cardiovascular collapse.

During surgical resection, hydrostatic pressure is usually higher than intravascular pressures, mainly in the venous bed, allowing intravasation of irrigation solution from the surgical field to the intravascular space. The greater the difference between these hydrostatic pressures, the higher the flow rate into the blood and the higher the risk of fluid overload. Moreover, although it is important to control surgical time and to keep distension pressure as low as possible, fluid overload may occur before the predicted period.

Preventive measures, such as low-pressure irrigation, might reduce the extent of fluid absorption but does not eliminate this complication. Monitoring the extent of absorption during surgery allows control of the fluid balance in the individual patient.

Report describing the clinical association between irrigation fluid temperature to intravasation rate itself or the risk of fluid overload are limited mainly to theoretical models. Benefits of cold irrigation fluids are reported in studies on transurethral prostatic resection (TUR) and include shorter procedure duration, improved surgical visualization, less fluid use and reduced blood loss. The results of studies demonstrating higher complication rate with hypothermia caused by locally applied cold irrigation solutions are equivocal and were not demonstrated specifically in hysteroscopic procedures.

The application of warm distension fluid has been recently used in office hysteroscopy in order to reduce pain severity. A recent meta-analysis including 5 randomized control trials reported warm saline was linked to a significant reduction in the visual analog scale (VAS) pain score during the procedure and higher patient satisfaction rate. Nevertheless, warm irrigation solution might be limiting for longer procedures due to expected expansion of the vascular system resulting higher fluid deficit in shorter time.

Due to the aforementioned, we aim to evaluated the role of temperature on absorption of the irrigation solution in hysteroscopic surgery.

Material and Methods This is a prospective study that will be conducted at a single tertiary medical center. Study population will include all women undergoing hysteroscopic surgery due to benign indication. Women with known malignancy or hysteroscopic procedures using alternative solutions (Ringer's lactate, 1.5% glycine, 5% dextrose) will be excluded from the study.

A TruClear™ hysteroscope will be used with 0.9% saline solution as the expanding media. Three different temperatures will be randomly assigned to each case including: 17°C, 24°C (room temperature), and 37°C (body temperature). The distension fluid will be prepared in advance using cooled standardized refrigerator for the 17°C solution, and heating incubator for the 37°C and room temperature for the 24°C solution. The liquid temperatures will be confirmed by thermometer before the procedure. Randomization to each arm will be made using computer randomizer. The time to reach fluid deficit will be measured at the following deficit points: 250 cc, 500 cc, 750 cc, 1000cc, 1500 cc and total deficit. In addition, presurgical and post-surgical blood samples for sodium level and osmolality will be collected. Immediate post-surgical pain will be assesses 1 hour following the procedure using the visual analog scale.

Demographic and clinical characteristics will be drawn from women's medical files. Operative and post-operative data will be collected including: operation indication, operation duration, operation complications (uterine perforation, bleeding, fluid overload complications- electrolyte disturbances, osmolality, pulmonary embolism, pulmonary oedema), post-operative complications (hemorrhage, endometritis, vascular - thromboembolic event, ileus).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
The Influence of Solution Temperature on Fluid Deficit During Hysteroscopy
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Warmed saline

0.9% Saline will be warmed to 37 degrees Celsius

Other: 0.9% Saline warmed to 37 degrees Celsius
0.9% Saline warmed to 37 degrees Celsius

Experimental: Room temperature saline

0.9% Saline will be warmed to 24 degrees Celsius

Other: 0.9% Saline warmed to 24 degrees Celsius
0.9% Saline warmed to 24 degrees Celsius

Experimental: Cooled Saline

0.9% Saline will be cooled to 17 degrees Celsius

Other: 0.9% Saline cooled to 17 degrees Celsius
0.9% Saline cooled to 17 degrees Celsius

Outcome Measures

Primary Outcome Measures

  1. Median time to reach deficit of 500 cc [From recruitment until follow up visit 2 weeks post operation]

    The difference to reach deficit of 500 cc in each arm

Secondary Outcome Measures

  1. Visual analog scale (VAS) [1 hour after the procedure]

    To estimate pain post operation on a scale of 1 to 10 while 1 is no pain and 10 is maximal pain

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • All women undergoing gynecologic hysteroscopic surgery.
Exclusion criteria:
  • Women with known malignancy

  • hysteroscopic procedures using alternative solutions (Ringer's lactate, 1.5% glycine, 5% dextrose)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • The University of Texas Health Science Center, Houston

Investigators

  • Principal Investigator: Aya Mohr-Sasson, The University of Texas Health Science Center, Houston, TX

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Aya Mohr Sasson, Principle investigator, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT05622097
Other Study ID Numbers:
  • HSC-MS-22
First Posted:
Nov 18, 2022
Last Update Posted:
Nov 18, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 18, 2022